CRSP logo

CRSP
CRISPR Therapeutics AG

41,782
Mkt Cap
$4.39B
Volume
1.62M
52W High
$78.48
52W Low
$30.04
PE Ratio
-7.02
CRSP Fundamentals
Price
$44.34
Prev Close
$45.75
Open
$45.89
50D MA
$52.44
Beta
1.54
Avg. Volume
1.69M
EPS (Annual)
-$6.47
P/B
2.28
Rev/Employee
$8,931.30
$2,938.96
Loading...
Loading...
News
all
press releases
Cathie Wood sells $2.1 million of megacap tech stock
false
TheStreet.com·3d ago
News Placeholder
More News
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $148,853.96 in Stock
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) General Counsel James Kasinger sold 3,182 shares of the firm's stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $148,853.96. Following the transaction, the...
MarketBeat·5d ago
News Placeholder
Truist Financial Upgrades CRISPR Therapeutics (NASDAQ:CRSP) to "Strong-Buy"
Truist Financial upgraded shares of CRISPR Therapeutics to a "strong-buy" rating in a research note on Wednesday...
MarketBeat·5d ago
News Placeholder
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.
Zacks·5d ago
News Placeholder
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,182 Shares
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) General Counsel James Kasinger sold 3,182 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average...
MarketBeat·6d ago
News Placeholder
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning Anti-Aging Protein Research Takes a Step Forward with Cell Cloning PR Newswire VANCOUVER, BC, March 24, 2026 Issued on behalf of Ava...
PR Newswire·6d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks·6d ago
News Placeholder
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?
Key PointsCRISPR recently raised nearly $600 million through a private offering, which weighed down its share price...
Nasdaq News: Markets·7d ago
News Placeholder
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Analysts
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has been assigned an average rating of "Hold" from the eighteen research firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, six have given a hold recommendation an...
MarketBeat·8d ago
News Placeholder
JPMorgan Chase & Co. Has $38.46 Million Holdings in CRISPR Therapeutics AG $CRSP
JPMorgan Chase & Co. lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 98.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 593,416 shares of the company's stock afte...
MarketBeat·9d ago
<
1
2
...
>

Latest CRSP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.